WCDG meets monthly September to May and typically on the 3rd Wednesday of the month, unless otherwise noted. Meetings are public and include a light dinner & social hour followed by a speaker.
Email us at email@example.com. Follow us on LinkedIn.
New to analytical chemistry or looking to sharpen your skills? Visit NIST’s site for videos and PowerPoints on Tutorials in Analytical Chemistry
Wednesday, December 12, 2018 at USP
Dinner & Social 6pm, Lecture 7pm
Featured Speaker: Perry Wang, FDA
Title: Identification and Quantitation of 16 PAHs in Tattoo Inks by UHPLC-APPI-MS/MS with Scheduled Selected Reaction Monitoring
Abstract: A method using ultrahigh performance liquid chromatography with APPI tandem mass spectrometry (UHPLC-APPI-MS/MS) with a fast sample preparation procedure was developed to determine the 16 U.S. EPA priority pollutant polycyclic aromatic hydrocarbons (PAHs) in tattoo inks. Scheduled selected reaction monitoring (sSRM) was applied to increase the sensitivity. Sixteen corresponding deuterated PAHs were used as internal standards to compensate for recovery and matrix effects. The method was validated and successfully applied to survey 78 commercial tattoo ink products. The coefficient of determination (r2) is greater than 0.99 for all sixteen analytes and the recovery ranged from 92.5% to 106% at three spiked levels. Ten PAHs were found in nine out of the fourteen black tattoo inks with concentrations ranging from 0.25 to 17 μg/g (ppm). Only three PAHs including fluoranthene, phenanthrene, and benzo[b]fluoranthene were found in twenty out of the sixty-four colored tattoo inks within a range of 0.10 to 8.5 μg/g. To date, this is the first UHPLC-APPI-MS/MS method using sSRM and stable isotopically labeled internal standards to simultaneously determine 16 PAHs in tattoo inks.
Bio: Dr. Perry G. Wang is a research chemist in the Office of Regulatory Science, CFSAN at US FDA. Prior to joining the FDA, Dr. Wang worked in the pharmaceutical and medical-device industries. His expertise in the pharmaceutical field focuses on high throughput drug analysis and validation by LC-MS/MS. His current research at the FDA includes developing analytical methods for chemical constituents and contaminants in cosmetics and personal care products by GC-MS/MS and LC-MS/MS. He received his Ph.D. degree at Oregon State University.